MIRA Pharmaceuticals, Inc. (MIRA)
Nasdaq: MIRA · Pharmaceutical Preparations · Miami, FL · filing with the SEC since 2022
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Mar 31, 2026 | Mar 28, 2025 | Apr 1, 2024 | · |
| For lenders | ||||
| Net interest income | 98,911 | 165,669 | · | · |
| Research and development | 1,719,783 | 3,305,575 | 1,572,962 | 2,351,465 |
| General and administrative | 8,773,329 | 4,712,753 | 6,499,537 | 2,992,125 |
| Total operating expenses | 10,493,112 | 8,018,328 | 8,526,049 | 7,047,940 |
| Interest expense | · | -165,669 | 3,456,294 | 10,250 |
| Other income (expense), net | 50,627 | 165,669 | · | · |
| Total non-operating income (expense) | 50,627 | 165,669 | · | · |
| Net income | -10,442,485 | -7,852,659 | -11,982,343 | -7,058,190 |
| Preferred dividends | 21,556,821 | · | · | · |
| Net income to common shareholders | -31,999,306 | -7,852,659 | · | · |
| Earnings per share, basic | -1.35 | -0.51 | -0.85r | -0.5333b |
| Earnings per share, diluted | -1.35 | -0.51 | -0.85r | -0.5333b |
| Weighted average shares, basic | 23,694,333 | 15,444,149 | 13,924,619r | 13,174,900b |
| Weighted average shares, diluted | · | 15,444,149 | 13,924,619r | 13,174,900b |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 3-for-4 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Net interest income interest earned less interest paid
us-gaap:InterestIncomeExpenseNetResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesInterest expense what its borrowing cost
us-gaap:InterestExpenseOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossPreferred dividends paid to preferred holders before common shareholders
us-gaap:PreferredStockDividendsIncomeStatementImpactNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding